This study examined the neuroprotective effects of semaglutide, a glucagonlike peptide1 (GLP1) receptor agonist, in a rat model of CPinduced neuropathy
Other red flags include suppliers making explicit health or treatment claims, since legitimate research-use suppliers are careful to frame their products strictly for laboratory and research applications rather than implying therapeutic use
current licensed UK options for weight management include orlistat and semaglutide 2.4 mg (Wegovy) under TA875
[43] analyzing a nationwide claims database, reported increased risks of new-onset depression, anxiety, and suicidal ideation among GLP-1 RA users, especially in women and younger individuals
Liang W, Qi Y, Yi H, Mao C, Meng Q, Wang H, Zheng C (2022) The roles of adipose tissue macrophages in human disease
Here's a quick reference table that outlines the FDA-approved GLP-1 receptor agonists, including their brand names and approval dates